| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED DECEMBER 2017. Refer to TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | lenvatinib (Kisplyx®) | |
| Formulation | 4 mg hard capsule, 10 mg hard capsule | |
| Reference number | 3290 | |
| Indication | In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF)-targeted therapy |
|
| Company | Eisai Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 17/11/2016 | |
| Date of issue | 18/11/2016 | |
| NICE guidance | TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
|